Skylar Jeremias

Chronic kidney disease complicates cancer treatment, leading to reduced chemotherapy use. Personalized approaches are essential for optimal patient outcomes.

The FDA approved subcutaneous mosunetuzumab for relapsed follicular lymphoma, providing a more convenient outpatient option.

A new study links immune markers and coping patterns to disease control in adolescents with chronic urticaria.

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza.

The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.

Experts advocate for a shift in CKD care towards prevention and maintaining kidney health, emphasizing lifestyle changes and early interventions.

Explore safe IBD treatment options for patients with chronic kidney disease, focusing on tailored approaches to optimize kidney health and medication efficacy.

Experts discuss the evolving dynamics between payers and providers in oncology, emphasizing value-based care, data transparency, and collaborative reform opportunities.

The patient was a rare case of a patient with dedifferentiated liposarcoma and a high tumor mutational burden.

Discover key insights from the ERS Congress 2025, highlighting advancements in pulmonary fibrosis treatment and the promising role of nerandomilast.

Recent studies highlight ustekinumab's effectiveness and safety in treating Crohn disease, especially for patients unresponsive to prior therapies.

A low-protein diet is essential for managing chronic kidney disease (CKD), potentially slowing progression and improving health outcomes while tailoring to individual needs.

Epcoritamab combined with rituximab and lenalidomide significantly improves outcomes for relapsed follicular lymphoma, setting a new treatment standard.

New trial results reveal fixed-duration venetoclax regimens match continuous ibrutinib therapy in CLL, enhancing patient quality of life and adherence.

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

A study reveals real-world effects of switching to adalimumab biosimilar Hyrimoz, highlighting flare rates and injection pain concerns in inflammatory disease patients.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

With ACA subsidies and key CMS payment models ending in 2025, premiums are set to rise, shifting costs to consumers and employers.

A study identifies tumor stage and stoma status as key drivers of diminished quality of life among patients with colorectal cancer.

While artificial intelligence showed empathy and precision in respiratory health care, its equitable adoption is paramount to prevent the widening digital divide, as highlighted at the European Respiratory Society Congress 2025.

The FDA has approved pembrolizumab and enfortumab vedotin for muscle-invasive bladder cancer (MIBC), offering new hope for patients ineligible for cisplatin.

Lower-income countries rarely gain timely access to FDA-approved drugs tested in their populations, highlighting major global and ethical disparities.

Foster and kinship care children formed stronger bonds with carers, but relationship quality didn’t predict later emotional outcomes, a study finds.

RPM may improve patient access to care, especially those with high-risk conditions, but not without a significant cost.

Early-onset colorectal cancer (CRC) increases are linked to neuroendocrine tumor reclassification, not true adenocarcinoma growth.

Children and adults should watch where they are walking and avoid any thrown objects when participating in Halloween festivities to protect their eyes.

The FDA announced draft guidance to remove clinical efficacy studies for biosimilars and also issued the position that all biosimilars in the US should be interchangeable.

Chelsea Renfro, PharmD, discusses the importance of rigorous study designs to establish medication efficacy.

Posters presented at AMCP Nexus 2025 found especially low oral HIV PrEP uptake among transgender individuals and those facing insurance challenges.

Payers cited high upfront costs, long-term uncertainty, and narrow coverage criteria as factors continuing to limit access and reimbursement innovation.